Galderma Group
Tracked across 1 events · 6 articles · First seen May 21, 2026 · Last active Jul 01, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Galderma Group received a Complete Response Letter from the United States — Food and Drug Administration regarding its Biologics License Application for RelabotulinumtoxinA, delaying its U.S. market entry. This impacts Galderma Group's goal of global leadership in injectable aesthetics.
Jul 01, 2026 · 6 articles
100
United States — Food and Drug Administration issued Complete Response Letter Galderma GroupGalderma...
80
United States — Food and Drug Administration conducted Pre-License Inspection Galderma GroupGalderma...
70
Galderma Group received Complete Response Letter United States — Food and Drug AdministrationGalderma...
ERGEN INTELLIGENCE
Track Galderma Group live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard